Table 1.
Baseline characteristics
| All patients (n = 68) | TACE alone (n = 24) | TACE + TAI (n = 44) | P value | |
|---|---|---|---|---|
| Gender (male/female) | 51/17 | 20/4 | 31/13 | 0.24 |
| Age (years) | 71 ± 8 | 72 ± 6 | 70 ± 9 | 0.42 |
| Etiology of liver disease (HBV/HCV/NBNC) | 5/50/13 | 3/18/3 | 2/32/10 | 0.33 |
| Previous treatment (surgical/local/non) | 3/30/35 | 2/15/7 | 1/15/28 | 0.0066 |
| Child‐Pugh class (A/B) | 43/23 | 15/8 | 28/15 | 0.91 |
| Child–Pugh score (5/6/7/8/9) | 28/15/10/12/1 | 11/4/4/3/1 | 17/11/6/9/0 | 0.61 |
| Stage (I/II/III/IVA) | 7/22/33/6 | 5/5/14/0 | 2/17/19/6 | 0.023 |
| Vp (−/+) | 58/6 | 23/1 | 36/5 | 0.45 |
| Number of tumor (1/2/3/>3) | 15/6/4/42 | 6/3/1/14 | 9/3/3/28 | 0.73 |
| Tumor diameter (mm) | 31.1 ± 15.5 | 27.2 ± 14.5 | 33.2 ± 15.7 | 0.13 |
| AFP (ng/mL) | 48 (11–212) | 52 (17–193) | 44 (11–213) | 0.52 |
| DCP (mAU/mL) | 89 (27–682) | 52 (23–1072) | 105 (30–682) | 0.56 |
| Creatinine (mg/dL) | 0.85 ± 0.32 | 1.02 ± 0.41 | 0.75 ± 0.22 | 0.0009 |
| Platelets (×104/mm3) | 9.9 ± 4.6 | 10.3 ± 4.7 | 9.8 ± 4.6 | 0.64 |
| ALT (IU/mL) | 58 ± 45 | 65 ± 63 | 54 ± 32 | 0.31 |
| AST (IU/mL) | 66 ± 38 | 65 ± 39 | 67 ± 37 | 0.81 |
| Albumin (g/dL) | 3.5 ± 0.5 | 3.6 ± 0.5 | 3.5 ± 0.5 | 0.19 |
| Total bilirubin (mg/dL) | 1.3 ± 0.7 | 1.1 ± 0.7 | 1.3 ± 0.6 | 0.19 |
| Prothrombin time (%) | 75.1 ± 11.5 | 73.3 ± 11.9 | 76.1 ± 11.5 | 0.34 |
| Dose of epirubicin (mg) | 25 ± 24 | 34 ± 29 | 20 ± 14 | 0.010 |
| Dose of lipiodol (mL) | 7.3 ± 4.3 | 7.1 ± 4.2 | 7.3 ± 4.4 | 0.85 |
P values represent the results of the comparison between TACE alone group and TACE with TAI group.
AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DCP, des‐gamma‐carboxy prothrombin; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, both negative for HBV and HCV; TACE, transcatheter arterial chemoembolization; TAI, transcatheter arterial infusion; Vp, portal vein tumor thrombosis.